Regen BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2015 - 2019
Net Income	-1.13	-0.87	1.16	2.44	-6.77	3.41	Upgrade
Other Amortization	0.05	0.03	0	0.07	0.05	0.61	Upgrade
Loss (Gain) From Sale of Investments	0.2	0.2	-	-0.03	1.16	-	Upgrade
Stock-Based Compensation	0.16	0.15	0.25	0.05	0	0	Upgrade
Other Operating Activities	-0	-	0.35	0	-1.87	-	Upgrade
Change in Accounts Receivable	-0.11	-0.09	0.25	-0.04	-0.11	-0.03	Upgrade
Change in Accounts Payable	0	-0	0	-0.06	-0.02	0.02	Upgrade
Change in Unearned Revenue	-0.13	-0.14	-0.11	-0.13	1.84	-	Upgrade
Change in Other Net Operating Assets	0.47	0.02	-2.07	-2.91	4.59	-3.99	Upgrade
Operating Cash Flow	-0.49	-0.69	-0.17	-0.61	-1.13	0.02	Upgrade
Investment in Securities	-	-	-	0.03	0.5	-	Upgrade
Investing Cash Flow	-	-	-	0.03	0.5	-	Upgrade
Short-Term Debt Issued	-	0.02	0.24	0	1.36	-	Upgrade
Total Debt Issued	0.19	0.02	0.24	0	1.36	-	Upgrade
Short-Term Debt Repaid	-	-	-	-	-	-0.03	Upgrade
Long-Term Debt Repaid	-	-0.01	-	-0.09	-	-	Upgrade
Total Debt Repaid	0.06	-0.01	-	-0.09	-	-0.03	Upgrade
Net Debt Issued (Repaid)	0.25	0.01	0.24	-0.09	1.36	-0.03	Upgrade
Issuance of Common Stock	0.16	0.56	-	-	-	-	Upgrade
Financing Cash Flow	0.41	0.57	0.24	-0.09	1.36	-0.03	Upgrade
Miscellaneous Cash Flow Adjustments	-0	-	-	-0	-	-	Upgrade
Net Cash Flow	-0.08	-0.12	0.07	-0.68	0.73	-0.01	Upgrade
Cash Interest Paid	0.02	0.02	-	0.03	-	-	Upgrade
Levered Free Cash Flow	0.06	-0.41	-2.56	-4.04	5.79	-4.15	Upgrade
Unlevered Free Cash Flow	0.1	-0.38	-2.52	-3.98	5.97	-4.17	Upgrade
Change in Net Working Capital	-0.17	0.27	2.34	3.81	-6.1	4.04	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.